Jump to content

Felcisetrag

From Wikipedia, the free encyclopedia

Felcisetrag
Identifiers
  • methyl 4-[[4-[[(2-propan-2-yl-1H-benzimidazole-4-carbonyl)amino]methyl]piperidin-1-yl]methyl]piperidine-1-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H37N5O3
Molar mass455.603 g·mol−1
3D model (JSmol)
  • CC(C)C1=NC2=C(C=CC=C2N1)C(=O)NCC3CCN(CC3)CC4CCN(CC4)C(=O)OC
  • InChI=1S/C25H37N5O3/c1-17(2)23-27-21-6-4-5-20(22(21)28-23)24(31)26-15-18-7-11-29(12-8-18)16-19-9-13-30(14-10-19)25(32)33-3/h4-6,17-19H,7-16H2,1-3H3,(H,26,31)(H,27,28)
  • Key:MZOITCJKGUIQEI-UHFFFAOYSA-N

Felcisetrag (TAK-954, TD-8954) is a drug which acts as a potent and highly selective agonist for the serotonin receptor 5-HT4. It is in clinical trials for the treatment of gastroparesis.[1][2][3][4]

References

[edit]
  1. ^ Chedid V, Brandler J, Arndt K, Vijayvargiya P, Wang XJ, Burton D, et al. (May 2021). "Randomised study: effects of the 5-HT4 receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis". Alimentary Pharmacology & Therapeutics. 53 (9): 1010–1020. doi:10.1111/apt.16304. PMC 8251541. PMID 33711180.
  2. ^ Pusalkar S, Chowdhury SK, Czerniak R, Zhu X, Li Y, Balani SK, et al. (May 2022). "Clinical and Nonclinical Disposition and In Vitro Drug-Drug Interaction Potential of Felcisetrag, a Highly Selective and Potent 5-HT4 Receptor Agonist". European Journal of Drug Metabolism and Pharmacokinetics. 47 (3): 371–386. doi:10.1007/s13318-021-00751-8. PMC 9050781. PMID 35157234.
  3. ^ Patel P, Zaher EA, Khataniar H, Ebrahim MA, Loganathan P (January 2024). "Safety and Efficacy of Highly Selective 5-Hydroxytryptamine Receptor 4 Agonists for Diabetic and Idiopathic Gastroparesis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Cureus. 16 (1): e51851. doi:10.7759/cureus.51851. PMC 10848606. PMID 38327939.
  4. ^ Boeckxstaens G, Ayad S, Dukes G, Essandoh M, Gryder R, Kamble P, et al. (August 2024). "A randomized phase 2 study of the 5-HT4 receptor agonist felcisetrag for postoperative gastrointestinal dysfunction after bowel surgery". American Journal of Surgery. 234: 162–171. doi:10.1016/j.amjsurg.2024.04.030. PMID 38724293.